drug
IRBESARTAN
Marketedupdated 3mo agoby Hisun Pharmaceutical USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval214 co-mentions · 107 sources
- drugALDACTAZIDE152 co-mentions · 76 sources
- tagSmall Molecule107 co-mentions · 107 sources
- drugIRBESARTAN AND HYDROCHLOROTHIAZIDE76 co-mentions · 76 sources
- companyAurobindo Pharma Ltd20 co-mentions · 20 sources
- companyLupin Ltd10 co-mentions · 10 sources
- companyHetero Labs Ltd7 co-mentions · 7 sources
- companyJubilant Generics Ltd5 co-mentions · 5 sources
indications
investigational
Hypertension
all catalysts(31)
approval · 31
Sep 27, 2012
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Sep 27, 2012
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Oct 3, 2012
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Mar 11, 2013
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Sep 15, 2014
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Sep 22, 2014
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Feb 23, 2015
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 6, 2015
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 28, 2015
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Aug 9, 2016
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Aug 9, 2016
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Aug 9, 2016
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Aug 9, 2016
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 2, 2016
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Oct 24, 2018
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 13, 2018
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 6, 2019
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 30, 2020
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
May 6, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
May 6, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Sep 1, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 8, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 8, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Dec 20, 2021
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Feb 28, 2022
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 1, 2022
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Sep 30, 2025
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Oct 1, 2025
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 4, 2025
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 12, 2025
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Nov 25, 2025
approval
IRBESARTAN — FDA approval
IRBESARTAN
→
Trials studying IRBESARTAN
- phase3A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- phase3Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- phase3Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
- phase3A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- phase2Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
- phase3Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia
- phase3Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
- phase2A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that